Acorn Bioventures Discloses New 3.9% Stake in Karyopharm Therapeutics Inc.

On May 15, 2026, Acorn Bioventures, L.P. and associated entities filed a Schedule 13G regarding their holdings in Karyopharm Therapeutics Inc. (KPTI). The filing reveals that Acorn Bioventures 2, L.P. acquired 880,505 shares of Common Stock, representing a 3.9% ownership stake based on the shares outstanding as of May 7, 2026. Additionally, Acorn Bioventures, L.P. reported holding 637,608 shares (2.8%). Anders Hove, serving as the Manager of the General Partners for both Acorn entities (Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC), may be deemed to have shared voting and dispositive power over a combined total of 1,518,113 shares. This aggregate holding represents approximately 6.7% of the issuer's outstanding common stock. The acquisition was made in the ordinary course of business and not for the purpose of influencing control over the company. The reporting persons are based in New York and organized under Delaware law.